Drugs / HD204
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT03390673 | Sep 2018 → Mar 2019 | — | Prestige Biopharma Limited | Completed | Met primary |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT03390686 | Nov 2019 → Jul 2024 overdue | non-small cell lung carcinoma | Prestige Biopharma Limited | Active not recruiting | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-24 | Prestige Biopharma Limited | Results Prestige Biopharma's Avastin Biosimilar HD204 Nears Regulatory Approval and Commercialization prestigebiopharma.com ↗
For the primary endpoint — objective response rate (ORR) at 18 weeks — HD204 achieved 48.7% versus 46.5% for reference Avastin, meeting pre-specified equivalence criteria and demonstrating clinical equivalence. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-24 | Prestige Biopharma Limited | Prestige Biopharma's Avastin Biosimilar HD204 Nears Regulatory Approval and Commercialization prestigebiopharma.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HD204 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03390686 ↗ |